. 2022 Dec 14;12(7):7772–7783. doi: 10.1002/cam4.5535

TABLE 1.

Patient characteristics (n = 263)

Age ^a (years)	74.0 (68.0–79.0)
Sex (Female/Male)	55/208
ECOG‐PS (0/1/≥2)	216/35/11
Body mass index (kg/m²)	23.7 (21.2–26.1)
Etiology of HCC (hepatitis B/C/B + C/non‐B, non‐C)	41/94/1/127
Albumin (g/dl) ^a	3.8 (3.4–4.1)
Total bilirubin (mg/dl) ^a	0.8 (0.6–1.1)
Platelet count (×10³/m³) ^a	13.7 (10.3–19.8)
Prothrombin time (%) ^a	88 (80–97)
α‐fetoprotein level (ng/ml) ^a	31.4 (6.5–298.8)
Child–Pugh score (5/6/≥7)	163/80/20
Tumor size (cm) ^a	3.1 (1.8–7.0)
Number of tumors in the liver (0/1/2/3/4/≥5)	16/61/34/23/24/128
BCLC stage (≤A/B/≥C)	21/100/142
Follow‐up duration ^a (months)	8.3 (5.2–11.8)

Abbreviations: BCLC, Barcelona Clinic Liver Cancer; ECOG‐PS, Eastern Cooperative Oncology Group Performance Status; HCC, hepatocellular carcinoma.

^{^a}

Data expressed as medians (interquartile range).